Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
NCT06872892 · View on ClinicalTrials.gov ↗
Study Summary
This study is open to adults and adolescents aged 12 to under 18 with bronchiectasis. People can participate in this study if they produce sputum and have had flare-ups (also called exacerbations). The purpose of this study is to find out whether a medicine called BI 1291583 helps people with bronchiectasis. Participants are put into 2 groups randomly, which means by chance. One group takes BI 1291583 tablets and the other group takes placebo tablets. A placebo tablet looks like the BI 1291583 tablet but does not contain any medicine. Participants take 1 tablet once a day for up to 1 year and 6 months. Participants are in the study for up to 1 year and 8 months. During this time, participants visit the study site up to 10 times and get about 13 phone calls from the site staff. Participants regularly complete a diary on a smartphone about their bronchiectasis symptoms and study doctors regularly check for any changes. The study doctors document when participants experience flare-ups. The number of flare-ups is compared between the participants who receive BI 1291583 and those who receive the placebo. The study doctors also regularly check participants' health and take note of any unwanted effects.
Conditions Studied
Interventions
- DRUG BI 1291583
- DRUG Placebo matching BI 1291583
Study Locations (20)
Florida
- Central Florida Pulmonary Group — Altamonte Springs
- Meris Clinical Research-Brandon-69466 — Brandon
- St. Francis Medical Institute — Clearwater
- North Florida/South Georgia Veterans Health System — Gainesville
- University of Florida College of Medicine — Jacksonville
- Mayo Clinic - Florida — Jacksonville
- University of Miami — Miami
- Essence MD Research — Naples
California
- Newport Native MD, Inc — Newport Beach
- Paradigm Clinical Research - Redding — Redding
- University of California Davis — Sacramento
- University of California San Francisco — San Francisco
- Ventura County Medical Center — Ventura
Arizona
- Dignity Health, St. Joseph's Hospital and Medical Center — Phoenix
- University of Arizona — Tucson
Alabama
- University of Alabama at Birmingham — Birmingham
Alaska
- Providence Medical Group Alaska — Anchorage
Colorado
- National Jewish Health — Denver
Connecticut
- Yale University School of Medicine — North Haven
District of Columbia
- Georgetown University — Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,755 participants |
| Start Date | 2025-06-09 |
| Est. Completion | 2028-10-12 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06872892
The ClinicalTrials.gov registry entry for NCT06872892 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,755 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 203 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Bronchiectasis appearing as the primary indexed condition, and to 2 interventions — of which BI 1291583 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06872892 reports 20 study locations spanning 8 distinct geographic areas — top geographies include Florida, California, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06872892 about?
NCT06872892 is a clinical study titled "The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis". This study is open to adults and adolescents aged 12 to under 18 with bronchiectasis. People can participate in this study if they produce sputum and have had flare-ups (also called exacerbations). The purpose of this study is to find out whether a medicine called BI 1291583 helps people with bronc...
What is the current status of trial NCT06872892?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,755 participants. The study started on 2025-06-09. Estimated completion is 2028-10-12.
What conditions does trial NCT06872892 study?
This clinical trial studies the following conditions: Bronchiectasis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06872892?
The interventions under investigation include: BI 1291583 (DRUG), Placebo matching BI 1291583 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06872892?
This trial is sponsored by Boehringer Ingelheim, which has 203 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06872892 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.